脓毒症休克启动血管加压素时儿茶酚胺剂量、乳酸与休克持续时间与院内死亡率的相关性
该回顾性观察研究纳入克利夫兰诊所医疗系统内1610例符合CDC成人脓毒症事件定义的脓毒症休克成人患者,所有患者均在接受儿茶酚胺类升压药基础上持续输注血管加压素。启动血管加压素时中位乳酸3.9 mmol/L、去甲肾上腺素当量剂量25 µg/min、距休克发生5.3小时,院内生存率41%。去甲肾上腺素当量剂量每增加10 µg/min(至60 µg/min上限),院内死亡比值增加20.7%(aOR 1.21,95%CI 1.09–1.34);超过60 µg/min后无此关联。乳酸与启动时机存在显著交互作用(p=0.02),乳酸升高与院内死亡线性相关,而距休克发生时间无关联。
要点
- 启动血管加压素时去甲肾上腺素当量剂量在≤60 µg/min范围内,每增加10 µg/min院内死亡比值增加20.7%(aOR 1.21,95%CI 1.09–1.34)。
- 去甲肾上腺素当量剂量超过60 µg/min时,与院内死亡无关联(aOR 0.96,95%CI 0.84–1.10)。
- 启动血管加压素时乳酸浓度越高,院内死亡线性增加;乳酸与启动时机存在显著交互作用(p=0.02)。
- 距休克发生时间与院内死亡无关联,提示休克持续时间本身不独立预测死亡。
- 队列院内生存率41%,启动血管加压素时中位乳酸3.9 mmol/L、去甲肾上腺素当量25 µg/min、距休克5.3小时。
适用人群与场景
- 成人脓毒症休克患者,符合美国CDC成人脓毒症事件定义,在克利夫兰诊所医疗系统多家医院住院。
- 所有患者均在接受儿茶酚胺类升压药基础上持续输注血管加压素作为辅助治疗。
诊断标准与关键阈值
- 脓毒症休克诊断采用美国CDC成人脓毒症事件定义。
- 启动血管加压素时记录去甲肾上腺素当量剂量、乳酸浓度及距休克发生时间。
- 去甲肾上腺素当量剂量分段界值为60 µg/min(≤60与>60 µg/min分别分析)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性观察研究,采用分段与多变量logistic回归;样本量1610例,多中心(克利夫兰诊所医疗系统内多家医院)。
- 人群:符合CDC成人脓毒症事件定义的脓毒症休克成人,均接受持续输注血管加压素辅助儿茶酚胺升压;平均APACHE III 109.0±35.1,SOFA 14.0±3.5,院内生存率41%。
- 启动血管加压素时中位(IQR):乳酸3.9 mmol/L(2.3–7.2),去甲肾上腺素当量剂量25 µg/min(18–40),距休克发生5.3小时(2.1–12.2)。
- 去甲肾上腺素当量剂量每增加10 µg/min(至60 µg/min),院内死亡aOR 1.21(95%CI 1.09–1.34);超过60 µg/min时aOR 0.96(95%CI 0.84–1.10)。
- 乳酸与启动时机对院内死亡存在显著交互作用(p=0.02);乳酸升高与院内死亡线性相关,距休克发生时间无关联。
证据类型、等级与局限
- 证据类型:回顾性观察性研究(非RCT),原文未给出证据等级或推荐强度。
- 局限:回顾性设计、观察性关联不能推断因果;原文未提及其他局限。
对床旁实践的改变
- 在脓毒症休克接受血管加压素辅助治疗的患者中,启动血管加压素时的去甲肾上腺素当量剂量(≤60 µg/min区间)和乳酸浓度可用于风险分层,剂量与乳酸越高院内死亡风险越高。
- 不应将距休克发生时间单独作为启动血管加压素的风险决策依据,原文未发现其与院内死亡关联。
- 原文为回顾性观察研究,去甲肾上腺素当量剂量与乳酸为关联而非因果,不能据此推断调整启动时机可改变死亡率。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the association of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality.
DESIGN: Retrospective, observational study using segmented and multivariable logistic regression to evaluate the associations of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality.
SETTING: Multiple hospitals within the Cleveland Clinic Health System.
PATIENTS: Adult patients who met criteria for septic shock based on the U.S. Centers for Disease Control and Prevention Adult Sepsis Event definition.
INTERVENTIONS: All patients received continuous infusion vasopressin as an adjunct to catecholamine vasopressors.
MEASUREMENTS AND MAIN RESULTS: In total, 1,610 patients were included with a mean Acute Physiology and Chronic Health Evaluation III 109.0 ± 35.1 and Sequential Organ Failure Assessment 14.0 ± 3.5; 41% of patients survived the hospital admission. At the time of vasopressin initiation, patients had median (interquartile range) lactate concentration 3.9 mmol/L (2.3-7.2 mmol/L), norepinephrine-equivalent dose 25 µg/min (18-40 µg/min), and 5.3 hours (2.1-12.2 hr) elapsed since shock onset. The odds of in-hospital mortality increased 20.7% for every 10 µg/min increase in norepinephrine-equivalent dose up to 60 µg/min at the time of vasopressin initiation (adjusted odds ratio, 1.21 [95% CI, 1.09-1.34]), but no association was detected when the norepinephrine-equivalent dose exceeded 60 µg/min (adjusted odds ratio, 0.96 [95% CI, 0.84-1.10]). There was a significant interaction between timing of vasopressin initiation and lactate concentration (p = 0.02) for the association with in-hospital mortality. A linear association between increasing in-hospital mortality was detected for increasing lactate concentration at the time of vasopressin initiation, but no association was detected for time elapsed from shock onset.
CONCLUSIONS: Higher norepinephrine-equivalent dose at vasopressin initiation and higher lactate concentration at vasopressin initiation were each associated higher in-hospital mortality in patients with septic shock who received vasopressin.
参考来源
- Sacha GL, Lam SW, Wang L, et al. Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock. Crit Care Med. 2022. PMID: 34582425. doi:10.1097/CCM.0000000000005317
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。